Skin Immunity Sample Collection Involving Blisters and Biopsies
Primary Purpose
Hyper-Immunoglobulin E. Syndrome (HEIS), Chronic Granulomatous Disease (CGD)
Status
Not yet recruiting
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Blister induction
Skin Biopsies
Sponsored by
About this trial
This is an interventional basic science trial for Hyper-Immunoglobulin E. Syndrome (HEIS) focused on measuring Hyper-Immunuglobulin E.Syndrome, Chronic Granulomatous Disease, Tumor Necrosis Factor Alpha, Staphylococcus Aureus
Eligibility Criteria
INCLUSION CRITERIA:
Meets one of the following:
- has documentation of HIES or CGD (patient populations); or
- does not have clinically apparent evidence of an immune defect or history of invasive or recurrent S. aureus infections (healthy volunteers).
Between the following age limits (inclusive):
- 18 and 65 years old for healthy volunteers;
- 7 and 65 years old for patients with CGD;
- 18 and 65 years old for patients with HIES.
- Willing to allow storage of blood, RNA, bacterial and fungal cultures, and other tissue samples for future research.
- Able to provide informed consent.
EXCLUSION CRITERIA:
The following exclusion criteria apply to all subjects:
- For individuals undergoing blister or skin biopsy procedures, history of keloid formation.
- Current or prior (within 3 months) anticoagulant or anti-platelet therapy (other than aspirin or non-steroidal anti-inflammatory drugs [NSAIDs]).
- Current or prior (within 3 months) use of immunomodulatory drugs (e.g., chemotherapy, steroids), except if approved by the principal investigator.
- Pregnancy.
- Any condition that, in the opinion of the investigator, contraindicates participation in the study.
Sites / Locations
- National Institutes of Health Clinical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
1
2
Arm Description
Blister Induction
Skin Biopsies
Outcomes
Primary Outcome Measures
Tumor necrosis factor alpha (TNFa) production by keratinocytes from patients with HIES versus healthy volunteers
Evaluate epithelial cell responses to cutaneous wounds and infections of keratinocytes and other cutaneous epithelial cells in patients with HIES or CGD and healthy volunteers.
T-cell infiltration as percent of total cell infiltration in patients with CGD versus healthy volunteers.
Identify cellular mediators that contribute to the inflammatory processthrough evaluation of infiltrating cell types.
Fold induction in genes related to wound healing.
Determine whether there are abnormalities in specific tissue repair pathways, such as epithelial to mesenchymal transition (EMT).
Secondary Outcome Measures
Full Information
NCT ID
NCT03921515
First Posted
April 18, 2019
Last Updated
October 24, 2023
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
1. Study Identification
Unique Protocol Identification Number
NCT03921515
Brief Title
Skin Immunity Sample Collection Involving Blisters and Biopsies
Official Title
Skin Immunity Sample Collection Involving Blisters and Biopsies
Study Type
Interventional
2. Study Status
Record Verification Date
July 24, 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 30, 2023 (Anticipated)
Primary Completion Date
September 30, 2024 (Anticipated)
Study Completion Date
September 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Background:
The way the body heals and protects itself from getting sick is called the immune response. Some people with weak immune systems get sick often or get rashes and skin infections. Researchers want to find out how the immune system and skin problems are related so they can help these people.
Objective:
To learn about how immune response and skin healing are related to each other.
Eligibility:
People ages 18-65 with hyper IgE syndrome or Job syndrome or people ages 7-65 with chronic granulomatous disease. Healthy volunteers ages 18 65 are also needed.
Design:
Participants will be screened with:
Medical history
Physical exam
Possible urine tests
Participants will have 1 to 3 visits within about a week. Visits will include the following:
Participants will have a wells device strapped to the inside of the forearm. It will suction the skin and pull the top layer away to form 8 blisters. The skin over the blisters and the liquid inside will be collected.
Participants will have up to 4 skin biopsies. A sharp tool will remove a small plug of skin from the forearm.
Participants may have blood and urine tests.
The skin on participants skin will be rubbed with a cotton swab.
Some participants will have an overnight visit. They will have the blister device placed back on the arm. The wells will be lined up over the blister wounds. The wells will be filled with either saline or the participant s blood serum. The device will be covered and left on the arm for up to 24 hours. Doctors will periodically remove some liquid from the wells.
Detailed Description
The incidence of community-associated (CA) staphylococcal infections, especially those caused by methicillin-resistant Staphylococcus aureus (MRSA), has increased in recent years. Skin and soft tissues are the primary sites for these infections. Although many patients without apparent underlying immune dysfunction suffer from recurrent and persistent skin infections with S.aureus, patients with conditions such as hyper immunoglobulin E syndrome (HIES, or Job s syndrome) and chronic granulomatous disease (CGD) are disproportionately affected. Although underlying host molecular defects responsible for some of these predisposing conditions have been uncovered in recent years, the skin immune response to S. aureus infections has not been elucidated in either healthy volunteers or susceptible populations. We hypothesize that the local skin response determines susceptibility to S. aureus skin infection.
In this sample collection protocol, we will perform exploratory evaluations of anti-staphylococcal immune responses in healthy volunteers, subjects with HIES, and subjects with CGD. Following screening and baseline procedures, including blood draw and skin swab, subjects will have the option to undergo blister induction, where a suction device will be used to induce skin blisters on the forearm. The tops of the blisters and blister fluid will be collected for research testing and storage for future research. An optional overnight inpatient stay may be performed to collect additional cellular infiltrates in response to autologous serum and/or sterile saline. Subjects may also have up to 4 skin punch biopsies from the forearm over the course of a week to capture wound healing progress and identify involved genes. All research procedures will be performed at the National Institutes of Health Clinical Center (NIH CC).
The primary objective of this research is to perform ex vivo assessment of wound healing pathways using a skin blister model and skin biopsies to obtain keratinocyte cultures and evaluate skin immune responses. We will use three experimental approaches: 1) ex vivo evaluation of anti-microbial responses and tissue remodeling through derivation of keratinocyte cultures from skin blisters and biopsies, 2) in vivo and ex vivo assessment of cellular response after blister induction using overnight exposure to autologous serum and/or sterile saline, and 3) evaluation of in vivo responses to skin biopsies. We anticipate that the research will provide critical new information on the human skin immune and remodeling responses and will have direct relevance for the development of vaccines, diagnostics, and therapeutics.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyper-Immunoglobulin E. Syndrome (HEIS), Chronic Granulomatous Disease (CGD)
Keywords
Hyper-Immunuglobulin E.Syndrome, Chronic Granulomatous Disease, Tumor Necrosis Factor Alpha, Staphylococcus Aureus
7. Study Design
Primary Purpose
Basic Science
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
70 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Other
Arm Description
Blister Induction
Arm Title
2
Arm Type
Other
Arm Description
Skin Biopsies
Intervention Type
Other
Intervention Name(s)
Blister induction
Intervention Description
Blister induction involves creating 8 blisters on the forearm and removing the tops of the blisters for primary cell culture derivation. After blister induction, subjects may have an optional overnight admission to assess cell infiltration in response to autologous serum and/or sterile saline solution.
Intervention Type
Other
Intervention Name(s)
Skin Biopsies
Intervention Description
The skin biopsies will involve up to 4 biopsies: 2 initial punch biopsies 2 mm in diameter, followed by a punch biopsy 3 (plus or minus 1) and 7 (plus or minus 2) days later using a 3 mm punch to encompass the initial biopsy sites, capturing the tissue at 3 and 7 days of healing.
Primary Outcome Measure Information:
Title
Tumor necrosis factor alpha (TNFa) production by keratinocytes from patients with HIES versus healthy volunteers
Description
Evaluate epithelial cell responses to cutaneous wounds and infections of keratinocytes and other cutaneous epithelial cells in patients with HIES or CGD and healthy volunteers.
Time Frame
Throughout study
Title
T-cell infiltration as percent of total cell infiltration in patients with CGD versus healthy volunteers.
Description
Identify cellular mediators that contribute to the inflammatory processthrough evaluation of infiltrating cell types.
Time Frame
Throughout study
Title
Fold induction in genes related to wound healing.
Description
Determine whether there are abnormalities in specific tissue repair pathways, such as epithelial to mesenchymal transition (EMT).
Time Frame
Throughout study
10. Eligibility
Sex
All
Minimum Age & Unit of Time
7 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
INCLUSION CRITERIA:
Meets one of the following:
has documentation of HIES or CGD (patient populations); or
does not have clinically apparent evidence of an immune defect or history of invasive or recurrent S. aureus infections (healthy volunteers).
Between the following age limits (inclusive):
18 and 65 years old for healthy volunteers;
7 and 65 years old for patients with CGD;
18 and 65 years old for patients with HIES.
Willing to allow storage of blood, RNA, bacterial and fungal cultures, and other tissue samples for future research.
Able to provide informed consent.
EXCLUSION CRITERIA:
The following exclusion criteria apply to all subjects:
For individuals undergoing blister or skin biopsy procedures, history of keloid formation.
Current or prior (within 3 months) anticoagulant or anti-platelet therapy (other than aspirin or non-steroidal anti-inflammatory drugs [NSAIDs]).
Current or prior (within 3 months) use of immunomodulatory drugs (e.g., chemotherapy, steroids), except if approved by the principal investigator.
Pregnancy.
Any condition that, in the opinion of the investigator, contraindicates participation in the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ashleigh A Sun
Phone
(301) 605-2896
Email
sunaa@niaid.nih.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Ian A Myles, M.D.
Phone
(301) 451-8420
Email
mylesi@niaid.nih.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ian A Myles, M.D.
Organizational Affiliation
National Institute of Allergy and Infectious Diseases (NIAID)
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Institutes of Health Clinical Center
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
Phone
800-411-1222
Ext
TTY8664111010
Email
prpl@cc.nih.gov
12. IPD Sharing Statement
Citations:
PubMed Identifier
17940231
Citation
Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK; Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007 Oct 17;298(15):1763-71. doi: 10.1001/jama.298.15.1763.
Results Reference
background
PubMed Identifier
14665659
Citation
Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, Johnson SK, Vandenesch F, Fridkin S, O'Boyle C, Danila RN, Lynfield R. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003 Dec 10;290(22):2976-84. doi: 10.1001/jama.290.22.2976.
Results Reference
background
PubMed Identifier
22282052
Citation
Myles IA, Datta SK. Staphylococcus aureus: an introduction. Semin Immunopathol. 2012 Mar;34(2):181-4. doi: 10.1007/s00281-011-0301-9. Epub 2012 Jan 27. No abstract available.
Results Reference
background
Links:
URL
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2019-I-0084.html
Description
NIH Clinical Center Detailed Web Page
Learn more about this trial
Skin Immunity Sample Collection Involving Blisters and Biopsies
We'll reach out to this number within 24 hrs